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Marburg virus (MARV) has a high fatality rate in hu-
mans, causing hemorrhagic fever characterized by
massive viral replication and dysregulated inflam-
mation. Here, we demonstrate that VP24 of MARV
binds Kelch-like ECH-associated protein 1 (Keap1),
a negative regulator of nuclear transcription factor
erythroid-derived 2 (Nrf2). Binding of VP24 to Keap1
Kelch domain releases Nrf2 from Keap1-mediated
inhibition promoting persistent activation of a pano-
ply of cytoprotective genes implicated in cellular
responses to oxidative stress and regulation of
inflammatory responses. Increased expression of
Nrf2-dependent genes was demonstrated both dur-
ing MARV infection and upon ectopic expression of
MARV VP24. We also show that Nrf2-deficient mice
can control MARV infection when compared to lethal
infection in wild-type animals, indicating that Nrf2 is
critical for MARV infection. We conclude that VP24-
driven activation of the Nrf2-dependent pathway is
likely to contribute to dysregulation of host antiviral
inflammatory responses and that it ensures survival
of MARV-infected cells despite these responses.
INTRODUCTION
Marburgvirus (MARV) causes lethal hemorrhagic fever in humans
(Ligon, 2005), while there is currently no vaccine or approved
treatment. Fatal MARV infection involves massive disseminated
viral replication and host immune dysregulation with uncon-
trolled cytokine secretion (for review, see Mohamadzadeh,
2009) and a septic-shock-like syndrome (Mahanty and Bray,
2004; Mehedi et al., 2011).
Of seven MARV structural proteins (Feldmann and Klenk,
1996), NP, VP30, VP35, and RNA-dependent RNA polymerase
L are required for RNA replication and transcription (Feldmann
et al., 1993). A single-surface glycoprotein, GP, mediates viral1026 Cell Reports 6, 1026–1036, March 27, 2014 ª2014 The Authorsentry (Volchkov et al., 2000; Will et al., 1993). The matrix protein
VP40 is involved in virus assembly and budding and antagonizes
interferon (IFN) signaling (Valmas and Basler, 2011; Valmas et al.,
2010). Little is known about viral protein VP24 function (Bamberg
et al., 2005). However, a recent mass spectrometry screen re-
vealed that filoviral VP24 proteins might have multiple potential
cellular partners (Pichlmair et al., 2012). In the case of Ebolavirus
(EBOV), another member of the Filoviridae family, VP24 has been
implicated in virus budding (Huang et al., 2002) and nucleo-
capsid assembly (Mateo et al., 2011a) and is an important path-
ogenicity factor, antagonizing IFN signaling and aiding adapta-
tion to new animal hosts (Mateo et al., 2010, 2011b; Reid et al.,
2006, 2007). Although causing apparently similar hemorrhagic
disease in humans,MARV and EBOV appear to use different pro-
teins and strategies to prevail over a host’s defense system. This
raises important questions concerning the role of MARV VP24;
specifically, what are the cellular partners of MARV VP24, and
what are its potentially novel functions in MARV replication that
may underlie its potent pathogenicity?
The cellular Nrf2 (nuclear factor erythroid 2-related factor 2)-
dependent pathway protects against environmental insults and
oxidative stress (Ma, 2013; Thimmulappa et al., 2006) and
maintains cellular redox balance by regulating endogenous anti-
oxidants, phase II detoxification enzymes, and other defensive
proteins via antioxidant response elements (AREs) in target
gene promoters (Jaiswal, 2004). Under quiescent conditions,
Nrf2 is cytoplasmic and bound to its repressor Keap1 (Kelch-like
ECH-associated protein 1) (Itoh et al., 1999). Keap1 constitutively
targets Nrf2 for ubiquitination and thus proteasomal degradation
by acting as a substrate adaptor for the Cul3-based E3 ubiquitin
ligase complex (Furukawa and Xiong, 2005; Kobayashi et al.,
2004). Under oxidative stress, Keap1 loses its ability to repress
Nrf2 via its proteosomal degradation (Kobayashi et al., 2006).
Nrf2 then translocates into the nucleus where it heterodimerizes
with Maf proteins (Motohashi et al., 2004), binds ARE-containing
promoters, resulting in enhanced expression of a range of antiox-
idant, cytoprotective genes (Itoh et al., 1999). Well-characterized
Nrf2-dependent genes include Heme Oxygenase-1 (HO1),
NAD(P)H dehydrogenasequinine-1 (NQO1), Glutamate Cysteine
Ligase (GCL), andGlutathioneS-transferaseA1 (GSTA1) (Jaiswal,
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Figure 1. MARV VP24 Interacts with Keap1
(A) Reciprocal immunoprecipitations of MARV VP24 and Keap1. N- and C-terminal myc-tagged VP24 were coexpressed with Keap1 (left panels). Twenty-four
hours posttransfection (p.t.), cell lysates were analyzed by western blot and coprecipitation using myc antibody followed by western blot using Keap1 and VP24
antibodies. Right panels: myc-tagged Keap1 and nontagged VP24were coexpressed. Cell lysates were assayed for protein expression and coprecipitation using
myc antibody followed by western blot using Keap1 and VP24 antibodies.
(legend continued on next page)
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2004). TheNrf2 pathway has also been implicated in innate immu-
nity by regulating cellular inflammation responses (Rushworth
et al., 2008; Thimmulappaet al., 2006). Recent evidence suggests
that Nrf2 acts in viral infection, though the underlying molecular
mechanisms remain poorly understood (Burdette et al., 2010;
Carvajal-Yepes et al., 2011; Cho et al., 2009; Gonza´lez-Gallego
et al., 2011; Zhang et al., 2009).
We now uncover a cellular partner of MARV VP24 and link this
interaction to the host response. Precisely, we show that MARV
hijacks the Nrf2-antioxidant defense system and that viral pro-
tein VP24 binds Keap1 via its Kelch domain, liberating Nrf2
from Keap1 control, and activating the Nrf2 pathway. Activation
of Nrf2 was observed upon transient expression of VP24 and
duringMARV infection. Experiments in Nrf2/mice further high-
light the significance of the Nrf2 pathway for Marburgvirus repli-
cation and pathogenicity.
RESULTS
MARV VP24 Binds Keap1 through Its Kelch Domain
To identify cellular partners of MARV VP24, we used a yeast dou-
ble-hybrid screening approach, fusing VP24 to a Gal4DNA bind-
ing domain and cellular proteins encoded by a human spleen
cDNA library to a Gal4-activation domain. VP24 of EBOV, which
was previously shown to interact with cellular karyopherins (Reid
et al., 2006, 2007), was used as control. As expected, the cDNAs
encoding for karyopherin a1, a5, and a6 were retrieved in control
experiments, thus validating the screening approach. However,
none of the karyopherins were among those cellular proteins
found to interact with MARV VP24. From 125 yeast colonies,
60 contained sequences corresponding to cellular Keap1, the
cytoplasmic repressor of Nrf2 (Table S1). Among these 60
cDNAs, the shortest fragment encoded the 244 carboxy-termi-
nal amino acids of Keap1. To confirm an interaction between
the two proteins, amino- and carboxy-terminal-tagged VP24
of MARV (myc-VP24 and VP24-myc) were coexpressed with
human Keap1 in 293T cells, and lysates were subjected to
immunoprecipitation with myc antibodies followed by western
blot analysis using Keap1 and VP24 antibodies. Both myc-
tagged VP24 constructs coprecipitated plasmid-expressed
Keap1 (Figure 1A, left panel, compare lanes 4 and 6 to lane 2).
The reciprocal immunoprecipitation confirmed an interaction be-
tween the two proteins, where nontagged VP24 coprecipitated a
myc-tagged Keap1 (Figure 1A, right panel, lanes 3 and 4). As ex-
pected, nontagged Keap1 and VP24 were not precipitated by
myc antibodies when these proteins were expressed without
myc-tagged partners (Figure 1A, left panel, lane 2, and right
panel, lane 3). We also demonstrated that endogenous Keap1
could be precipitated by MARV VP24 (Figure S1).(B) Schematic representation of Keap1 domain structure and Keap1 deletion mu
Tramtrack, Broad-complex domain (BTB), a BACK domain, a Kelch domain, and a
hybrid screen encodes 244 aa from the carboxy-terminal end of Keap1 (380–624
(C) Deletion of Kelch domain prevents MARV VP24 binding. Keap1 deletion mutan
Cells were analyzed 24 hr p.t. by western blot (left panels) and by coimmunopre
antibodies (right panels).
(D)Nrf2andMARVVP24bindKeap1 in a similarmanner.Myc-taggedKeap1Kelchd
with HA-tagged VP24 (left panels) or with HA-taggedNrf2 (right panels). Twenty fou
HAandmycantibodies (upper panels), or by coimmunoprecipitation usingHAantib
1028 Cell Reports 6, 1026–1036, March 27, 2014 ª2014 The AuthorsResolution of the 3D structure of Keap1 has provided insights
into the functional domains of this protein (Ogura et al., 2010). It
was important to identify which domain of Keap1 is responsible
for interaction with MARV VP24. The data obtained through
yeast screening suggested that the carboxy-terminal end of
Keap1 is likely to be involved in VP24 binding. To confirm this,
a set of myc-tagged Keap1 deletionmutantswas generated (Fig-
ure 1B). Keap1 deletionmutantsmyc-tagged at the amino-termi-
nal end and hemagglutinin (HA)-tagged VP24 were coexpressed
in 293T cells, and the interaction between the proteins was
analyzed by coprecipitation using HA antibodies (Figure 1C).
Keap1 deletion mutants lacking either the amino terminal part
(DN) or carboxy-terminal region (DCTR) were coprecipitated
with VP24 in amanner similar to that of the full-length Keap1 (Fig-
ure 1C, right panel, compare lanes 9 and 10 to lane 7). However,
a Keap1 mutant lacking the double glycine Kelch-repeat domain
(DKelch) completely lost the capacity to bind VP24 (Figure 1C,
right panel, lane 8). Because the Kelch domain has been
described as the Nrf2 binding site, we investigated whether
Keap1 mutants defective for Nrf2 binding interact with MARV
VP24 (Figure 1D). To address this question, a previously
described set of Keap1 Kelch domain mutants was generated
(Li et al., 2004a; Lo et al., 2006). First, we coexpressed myc-
tagged Keap1 mutants with HA-tagged Nrf2 and analyzed inter-
action by immunoprecipitation using HA antibodies. As ex-
pected, mutants containing alanine substitutions (Y334A,
R380A, N382A, and R415A) and Keap1 mutant S383P
possessed a reduced capacity to interact with Nrf2 (Figure 1D,
left panel). Myc-tagged Keap1 mutants and HA-tagged VP24
were then coexpressed in 293T cells, and lysates were analyzed
for interaction between Keap1 and MARV VP24. When
compared to the wild-type protein, all Keap1 mutants showed
a decrease in their abilities to bind MARV VP24 (Figure 1D, right
panel). Similar to the results obtained with Nrf2, Keap1 mutants
S383P and Y334A almost completely lost the ability to bind
VP24, whereas others showed a reduction in binding efficiency.
These results confirmed that the VP24 binding site is located
within the Keap1 Kelch domain and that the binding sites of
Nrf2 and VP24 are likely to overlap.
Next, we studied the interaction between Keap1 and MARV
VP24 using immunofluorescent analysis. Vero E6 cells were
transfected with plasmids expressing the proteins either alone
or in tandem, and their intracellular distribution was analyzed
(Figure 2). Notably, MARV VP24 expressed in the absence of
other ectopic proteins displayed a spotted perinuclear pattern
(Figure 2, top panels). Conversely, consistent with previous re-
ports, Keap1 expressed alone showed a homogenous cyto-
plasmic distribution (Kang et al., 2004). Strikingly, intracellular
localization of both proteins was dramatically altered whentants. Keap1 is composed of an Amino Terminal Region (NTR), a Bric-a-brac,
C-terminal Region (CTR). The shortest Keap1 cDNA retrieved in yeast double-
aa). All Keap1 deletion mutants were myc tagged at the amino terminal end.
ts were either expressed alone or coexpressed together with HA-tagged VP24.
cipitation using HA antibodies followed by western blot with VP24 and Keap1
omainmutants deficient inNrf2bindingwereexpressedeither aloneor together
r hours p.t., lysateswere analyzed bywestern blotting usingKeap1 and VP24 or
odies followedbywesternblotwithVP24andKeap1antibodies (bottompanels).
Figure 2. Coexpression of MARV VP24
and Keap1 Results in Intracellular
Relocalization of Both Proteins and Their
Colocalization
MARV VP24 and Keap1 were expressed alone
or in combination in Vero E6 cells. Sixteen hours
p.t., cells were fixed using acetone/methanol and
subjected to immunofluorescence analysis using
VP24 and Keap1 antibodies. Nuclei were stained
with DAPI.they were coexpressed. In effect, both proteins colocalized and
could be seen as patch-like aggregates distributed throughout
the cytoplasm (Figure 2, bottom panels).
MARV VP24 Induces Nrf2 Activation
Keap1 represses Nrf2 activity by binding cytosolic Nrf2, facili-
tating its ubiquitination and promoting proteasomal-mediated
degradation (Itoh et al., 1999). Based on our results, we hypoth-
esized that VP24 binding to Keap1 would impair Keap1-medi-
ated negative regulation of Nrf2. To verify this, we used a gene
reporter assay to monitor the activity of firefly luciferase ex-
pressed under the control of two different Nrf2-dependent ARE
promoters corresponding to HO1 and NQO1 genes. 293T cellsCell Reports 6, 1026–1036were transfected with combinations
of the following plasmids: pHHO1-ARE-
Luc or pmNQO1-ARE-Luc and phCMV-
Nrf2, pSPORT6-Keap1, p-RL-TK-Luc,
and phCMV-MARV-VP24 as indicated
(Figures 3A and 3B). Firefly luciferase ac-
tivity was normalized to renilla luciferase
expressed from pRL-TK plasmid that
served as a control. Firefly luciferase ac-
tivity markedly increased in cells express-
ing Nrf2. This induction was substantially
reduced upon coexpression of Nrf2
and Keap1. Importantly, expression of
MARV-VP24 restores firefly luciferase ac-
tivity inhibited by Keap1 for both HO1 and
NQO1 ARE-Luc reporters, and this effect
is VP24 dose dependent. Increased
reporter gene expression suggests that
Keap1 loses its ability to negatively
regulate Nrf2 function upon MARV VP24
binding, allowing free Nrf2 to activate
transcription of Nrf2-dependent genes.
Activation of the Nrf2 pathway by
MARV VP24 was further evaluated by
analysis of Nrf2-dependent gene expres-
sion. Data obtained show that MARV
VP24 is able to alleviate Keap1-mediated
inhibition of both NQO1 and HO1 expres-
sion in a VP24 dose-dependent manner
(Figures 3A and 3B, right panels). Next,
it was important to demonstrate that
MARV VP24 can also affect the expres-
sion of Nrf2-dependent genes whenneither Nrf2 nor Keap1 are overexpressed. 293T cells were
transfected with different amounts of phCMV-MARV-VP24 or
an empty vector and expression of NQO1 was assayed (Fig-
ure S2). This analysis showed an increase in NQO1 expression
in VP24-transfected cells in a dose- and time-dependent
manner, whereas very little NQO1 was detected in cells trans-
fected either with an empty vector or phCMV-EBOV-VP30
used as control. To provide mechanistic proof of the ability of
VP24 to release Nrf2 from its cytoplasmic association with
Keap1, we monitored the intracellular localization of Nrf2 in the
presence of MARV VP24 by immunofluorescence (Figure 4).
Vero E6 cells were transfected with plasmids expressing Nrf2
alone, or Nrf2 with Keap1, or Nrf2, Keap1, and VP24 together., March 27, 2014 ª2014 The Authors 1029
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Figure 3. MARV VP24 Induces Nrf2 Acti-
vation and Expression of Nrf2-Dependent
Genes
Reporter gene assay. Cells were transfected with
the following plasmids: phCMV (Mock), phCMV-
MARV-VP24 (VP24), pSPORT6-Keap1 (Keap1),
phCMV-Nrf2 (Nrf2), pHHO1-ARE-Luc (left panel)
or pmNQO1-ARE-Luc (right panel), and pRLTk-
Luc. Different amounts of phCMV-MARV VP24
were used as indicated. Twenty-four hours later,
cells were lysed, and firefly and renilla luciferase
activities were assayed. Firefly luciferase activity
was normalized to renilla luciferase activity.
Normalized values are shown relative to values
obtained from cells transfected with control
plasmid phCMV (A and B, left panels). The graph
represents the average values from three different
experiments; error bars show SEM (A and B, right
panels). Cell lysates were analyzed by western
blot using VP24, Nrf2, Keap1, HO1, NQO1, and
actin antibodies.Nrf2 expressed alone was found in the nuclei, whereas coex-
pression of Nrf2 and Keap1 resulted in a predominantly cyto-
plasmic localization of Nrf2. Coexpression of Nrf2 and Keap1
together with MARV VP24 resulted in relocalization of Nrf2
from the cytoplasm into the nuclei confirming that MARV VP24
releases Nrf2 from Keap1 binding. Competition between Nrf2
and VP24 for Keap1 binding was confirmed by IP experiments
(Figure S3). An increase in levels of VP24 expression causes a
simultaneous increase in the amount of Keap1-precipitated
VP24 and a reduction in the amount of Keap1-precipitated Nrf2.
Marburg Viruses Hijack the Cellular Nrf2-Dependent
Pathway
We then addressed the importance of the Nrf2 pathway during
MARV infection. First, using Vero E6 cells we demonstrated
that infection with MARV results in increasing levels of NQO1
over 8 days postinfection (Figure 5A) while causing apparent
cytotoxic effects (Figure 5B). Similar results were obtained with
293T cells (Figure S4). Using 293T cells, we also showed that
levels of NQO1 increased during the course of infection with
live MARV, whereas only low levels of NQO1 could be detected
when cells were inoculated with UV-inactivated virus and that
an enhanced NQO1 expression correlated with increasing levels
of VP24 synthesized during infection (Figure 5C). Remarkably,
there was no increase in NQO1 levels when the cells were1030 Cell Reports 6, 1026–1036, March 27, 2014 ª2014 The Authorsinfected with EBOV whose VP24 does
not interact with Keap1 (data not shown).
Contrary to MARV, infection with EBOV
causes higher and earlier cytotoxicity
and results in appearance of reactive ox-
ygen species detected using a fluores-
cent probe (Figure S5).
To demonstrate that the VP24-driven
upregulation of Nrf2 has significance un-
der physiological conditions, we used
mice as a model of infection. Adult miceare resistant to Marburgvirus infection. However, passaging of
marburgvirus RAVN in mice resulted in a mouse-adapted variant
(ma-RAVV) causing lethal disease. Importantly, the disease
caused byma-RAVV resembles that seen in nonhuman primates
withMARV and is also characterized by uncontrolled viremia and
high viral titers in the liver and other organs in infected animals
(Warfield et al., 2009). The ma-RAVV and Nrf2-deficient mice
(Nrf2/) are therefore a suitable model to address the impor-
tance of the Nrf2 pathway for replication and pathogenicity of
Marburgviruses. Because RAVN VP24 possesses several amino
acid changes compared to MARV VP24, we investigated
whether RAVN VP24 interacts with Keap1 using a coprecipita-
tion assay. Similar to MARV, RAVN VP24 is able to precipitate
Keap1 (Figure 5D). Furthermore both VP24 proteins showed a
similar ability to upregulate the Nrf2 pathway with an increase
in luciferase activity using an ARE-NQO1-luciferase reporter
assay (data not shown). Next, groups of wild-type and Nrf2/
mice were inoculated intraperitoneally with 1,000 plaque-form-
ing units (pfu) of thema-RAVV, and animals weremonitored daily
for the appearance of symptoms. Blood was sampled for virus
recovery on day 4 from four animals from each group and from
surviving animals on day 9.Wild-typemice uniformly succumbed
to infection within 8 days (Figure 5E, left panel) consistently
demonstrating typical clinical signs of MARV disease, including
ruffled, ungroomed fur, hunched posture, reduced activity, and
Figure 4. MARV VP24 Releases Nrf2 from
Keap1 Control and Facilitates Nrf2 Trans-
location into the Nuclei
Nrf2, Keap1, and MARV VP24 were expressed in
Vero E6 cells alone or in combination as indicated.
Sixteen hours posttransfection, cells were fixed
using acetone/methanol and subjected to immu-
nofluorescence analysis using VP24, Keap1, and
Nrf2 antibodies.weight loss. In contrast, Nrf2/ animals proved to be more
resistant. Remarkably, all Nrf2/ animals displayed disease
symptoms to varying degrees during the first 6–7 days of infec-
tion. The animals that showed greater signs of disease, suc-
cumbed to infection. Otherwise, 50% of the animals survived
infection, recovered, and appeared to remain healthy throughout
the period of observation, which lasted 19 days postinfection
(Figure 5E, right panel). These mice appeared to have a smooth,
groomed coat, were active, and demonstrated normal posture.
On day 4 postinfection, viral titers in the sera of wild-type and
Nrf2/ mice were shown to be lower in the case of Nrf2/ an-
imals (5.37 ± 1 3 105 versus 1.99 ± 0.9 3 105). Strikingly, no in-
fectious virus was detected in the sera of surviving mice on day 9
p.i. In conclusion, both in vitro experiments with live virus and
in vivo experiments with Nrf2-deficient mice strongly support
the notion that the Nrf2 pathway plays a critical role during Mar-
burgvirus infection and may contribute to high mortality rates.
DISCUSSION
The discovery of host factors involved in Marburg virus
replication elucidates the molecular mechanisms underlying
pathogenesis, and potentially the cellular pathways hijacked byCell Reports 6, 1026–1036other highly pathogenic viruses. Our
study provides evidence indicating that
MARV VP24 plays a critical role during
virus replication by binding Keap1, a
cytosolic repressor of Nrf2 and modu-
lating the function of the Nrf2-dependent
cytoprotective pathway devoted to
cellular redox balance (Ma, 2013) and
regulation of cellular inflammation re-
sponses (Rushworth et al., 2008; Thim-
mulappa et al., 2007). This VP24 function
is of particular interest for filovirus infec-
tion because the disease is characterized
by dysregulation of inflammatory re-
sponses (Baize et al., 2002; Mahanty
and Bray, 2004; Mohamadzadeh, 2009;
Rubins et al., 2007) and is associated
with oxidative stress at viral replication
sites (Geisbert et al., 2003; Sanchez
et al., 2004).
Here, an interaction between VP24
and Keap1 was revealed using several
approaches. Notably, we showed that
coexpression of VP24 and Keap1 led todramatic relocalization of both proteins. We show that MARV
VP24 upregulates expression of Nrf2-dependent genes in a
dose-dependent fashion by competing for Nrf2 binding sites
and preventing Keap1 from suppressing Nrf2. Using a series
of Keap1 mutants defective for Nrf2 binding (Li et al.,
2004a, 2004b; Lo et al., 2006), we find that Nrf2 and VP24
binding sites overlap. These results correlate well with those
using Keap1 deletion mutants to show that MARV VP24 targets
the Nrf2 binding site (the Keap1 Kelch domain) and are consis-
tent with interaction results seen in our initial double-hybrid
screen.
The structure of the Keap1:Nrf2 complex has been reported
(Padmanabhan et al., 2008) indicating that the Keap1 homo-
dimer binds to one Nrf2 molecule via two recognition sites, the
DLG and ETGE motifs in the Nrf2 Neh2 domain (Tong et al.,
2006). Although Keap1 shares a common binding site for the
DLG and ETGE motifs of Nrf2, this dual recognition has physio-
logical relevance (Tong et al., 2007). In the currently accepted
hinge-latch model of Keap1 inhibition of Nrf2, Keap1 recruits
Nrf2 via the ETGE motif, whereas the DLGmotif keeps the mole-
cule in a correct position for ubiquitination. MARV VP24 binding
to the Kelch domain would thus interfere with Keap1 binding to
both Nrf2 sites, thus providing a mechanism of the Nrf2 pathway, March 27, 2014 ª2014 The Authors 1031
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Figure 5. MARV Hijacks Nrf2-Dependent Pathway
(A–C) MARV infection results in enhanced NQO1 expression. (A and B) Vero E6 cells were either left uninfected or infected withMARV at a MOI of 2 and then were
monitored for 8 days p.i. for expression of cellular NQO1 and MARV VP24 (A) and appearance of cytotoxic effects (B). Cell lysates were analyzed by western blot
using VP24, NQO1, and actin antibodies. Despite apparent cytotoxic effects caused by MARV replication, comparable levels of b-actin were detected in mock-
and virus-infected cells on days 1 and 8 p.i. (lanes 1 and 3, and lanes 7 and 8, respectively). In virus-infected cells, NQO1 levels increased during the course of
(legend continued on next page)
1032 Cell Reports 6, 1026–1036, March 27, 2014 ª2014 The Authors
modulation. This may occur through Nrf2 displacement from the
Keap1 complex or through exhaustion of existing Keap1 by
MARV VP24 resulting in availability of newly synthesized Nrf2.
Overall, our results strongly support the idea that MARV VP24
prevents Keap1-dependent control of Nfr2, allowing Nrf2 nuclear
relocalization, and thus activation of Nrf2-dependent genes.
Importantly, increased Nrf2-dependent gene expression seen
in MARV-infected cells correlates with increasing VP24 synthe-
sis during infection. Notably, over an extended period of time,
MARV infection does not lead to cell damage despite apparent
cytotoxic effects caused by massive viral replication. This is in
sharp contrast to Ebolavirus infection, which does not activate
Nrf2, resulting in ROS synthesis and early cell death.
Results with Nrf2/mice further highlights the significance of
the Nrf2 pathway in Marburgvirus replication. Infection with both
Ebola- and Marburgvirus is characterized by dysregulated in-
flammatory responses (Baize et al., 2002; Mohamadzadeh,
2009; Rubins et al., 2007). Massive infiltration of inflammatory
cells to the infection site, along with elevated levels of chemo-
kines (MIP1a, MCP1, MIP1b, MIF, and IP10), and pro- (IFN-a, tu-
mor necrosis factor a [TNF-a], and interleukin 1b [IL-1b]) and
anti-inflammatory cytokines (IL-10, IL-1RA, and IL-6) and nitric
oxide and ROS release follow the infection course. Although in-
fected cells experience oxidative exposure during infection,
MARV VP24 would provide cytoprotection through sustained
Nrf2 activation. Here, we show better survival and lower viral
replication in Nrf2/ mice compared to wild-type animals. Sur-
viving Nrf2/ mice completely clear the virus and recover from
infection. We surmise that lack of VP24-induced Nrf2 pathway
activation in infected Nrf2/ mice likely results in elimination
of these cells via host defense mechanisms. In contrast to
MARV, infection of Nrf2/micewith RSV led tomore severe dis-
ease compared to wild-type mouse infection (Cho et al., 2009).
This may be explained by differences in pathological appear-
ance between the two infections. RSV infection causes massive
ROS release characterized by inflammation and respiratory dis-
orders. Absence of Nrf2 resulted in augmented inflammatory re-
actions, severe respiratory failure and death of Nrf2/ mice.
MARV infection has a systemic character and the severity of
the disease is determined by both virus replication rate and a
host’s inflammatory reactions. Perhaps loss of VP24-dependent
Nrf2 pathway activation in Nrf2/ animals reduces the ability of
infected cells to respond to oxidative conditions caused by infil-
tration of inflammatory cells providing better conditions for mice
survival. Survival of virus-infected cells in oxidative conditions
through Nrf2 activation has also been reported for hepatitis C vi-
rus (Burdette et al., 2010) and hepatitis B virus (Schaedler et al.,
2010), although the molecular mechanisms involved are unclear.infection. Quantification of NQO1 expression after normalization to actin levels is s
virus (nonreplicating control) or untreated MARV at equal MOI (MOI of 5). Cells w
western blot for expression of NQO1, MARV VP24, and actin.
(D) RAVN VP24 precipitates Keap1. Myc-tagged RAVN-VP24 (VP24) and human K
assayed for protein expression and coimmunoprecipitation using myc antibody
Of note: the amino acid sequence of the Kelch domain of Keap1 is highly conserve
for Nrf2.
(E) Nrf2/ mice are less sensitive to Marburgvirus infection than wild-type anim
toneally with 1,000 pfu ofmouse-adaptedMarburgvirus RAVN.Miceweremonitor
The graph represents three independent experiments; error bars represents SEM
CeInterestingly, increasing evidence indicates that certain tumor
types constitutively activate the Nrf2 pathway, thus increasing
their survival in the patient and enabling them to endure acute
exposure to ROS-generating chemotherapeutic agents (Hayes
and McMahon, 2009). Strikingly, missense mutations in Keap1
reduce Keap1 repression of Nrf2 and cause persistent Nrf2 acti-
vation. By acting continuously on the Nrf2 pathway, MARV infec-
tion causes its sustained activation perhaps in addition to oxida-
tive stress stimulus that may contribute to host inflammatory
response dysregulation.
Keap1, our identified MARV VP24 target, is involved in inflam-
matory response control through interaction with IkB kinase
IKKb (Lee et al., 2009). IKKb possesses the same ETGE and
DLGmotifs as Nrf2 and binds to Keap1 in a similar manner. Simi-
larly, Keap1 results in IKKb ubiquitination and degradation by the
proteasome machinery. Thus, MARV VP24 binding could pre-
vent Keap1-dependent IKKb degradation activating the NF-kB
pathway similar to the Nrf2 pathway. NF-kB controls expression
of diverse processes, including inflammatory responses and cell
survival. As NF-kB target genes include proinflammatory cyto-
kines (TNFa, IL-1, and IL-6) and chemokines (MCP1 and
MIP1a) upregulated during filoviral infection, we speculate that
through targeting Keap1 MARV may cause persistent activation
of this proinflammatory cellular pathway that could contribute to
dysregulation of cellular inflammatory responses during infec-
tion. Further study will assess the role of MARV VP24 in IKKb
degradation and on the NF-kB pathway.
Although a number of publications have suggested the impor-
tance of viral targeting of the oxidative stress pathway, to our
knowledge, the molecular mechanisms involved and the cellular
factors targeted by viral components have not yet been clearly
demonstrated (Gonza´lez-Gallego et al., 2011; Hosakote et al.,
2011; Schaedler et al., 2010; Schwarz, 1996; Zhang et al.,
2009). An intriguing possibility is that other viruses might also
hijack this pathway. Future experiments will identify the Keap1
binding site on MARV VP24 and, using the reverse genetics sys-
tem for MARV (Hoenen et al., 2011), test the effect of preventing
VP24-Keap1 interaction on virus replication and pathogenicity.
Additionally, it will be of interest to investigate whether other
Kelch domain containing cellular proteins may also bind MARV
VP24 and be involved in pathogenic viral replication.
In conclusion, we present a model whereby targeting Keap1,
viral VP24 hijacks the Nrf2 pathway and ensures better survival
of virus-infected cells despite massive host antiviral inflamma-
tory responses to infection. Through sensing disturbances in
intracellular redox balance, Keap1 can be seen as a cellular
‘‘sweeper’’ protein that regulates activity of various transcrip-
tional activators, including Nrf2 and IKKb, by targeting them forhown in (A), right panel. (C) 293T cells were either infected with UV-inactivated
ere lysed at the indicated days postinfection, and samples were analyzed by
eap1 were coexpressed in 293T cells. Cell lysates were collected 24 hr p.t. and
. Samples were analyzed by western blot using VP24 and Keap1 antibodies.
d between human andmouse, with no sequence change within the binding site
als. Mice (C57BL6 or Nrf2/, n = 12 per group) were administered intraperi-
ed daily for survival (left) andweight loss (right) over 16 days postadministration.
.
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degradation. In the presence of MARV VP24, Keap1 is no longer
able to perform this function, pushing the infected cell into a state
where transcriptional activation remains unchecked, altering in-
flammatory balance. As this virus targets immune cells respon-
sible for limiting viral infection, the dysregulation of usually
well-controlled inflammatory responses likely contributes to
the pathogenesis of MARV infection.EXPERIMENTAL PROCEDURES
Viruses
Viruses belonging to Filoviridae family, Marburgvirus genus, species Marburg
virus (MARV) variant Musoke, mouse-adapted Ravn virus (ma-RAVV) variant
Ravn (Warfield et al., 2009), and Ebolavirus genus, species Zaire Ebola virus
(EBOV) were used.
Cell Lines, Transfection, Infection, and Plasmids
293T, Huh7, and Vero E6 cells were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum (FCS). For transfection, cells
were grown for 24 hr to a confluence of 60%. Transfection of cells was per-
formed using Fugene HD (Roche) or TurboFect reagent (Thermo). Cells were
analyzed 24 hr posttransfection unless indicated otherwise. For infection, sub-
confluent Vero E6, 293T, or Huh7 cells were infected with MARV or EBOV at a
multiplicity of infection (MOI) 2 or 5, respectively. One hour postinfection, inoc-
ulum was removed, and cells were left with DMEM media containing 2.5%
FCS. Culture supernatants and cell lysates were collected daily as indicated.
Western blot analysis was performed with corresponding antibodies (see
Supplemental Experimental Procedures). Details of plasmid constructions
are provided in Supplemental Experimental Procedures.
Yeast Double-Hybrid Screen
Yeast double-hybrid screen was performed as described previously (Journo
et al., 2009). Details are provided in Supplemental Experimental Procedures.
Immunoprecipitation
Immunoprecipitations using mMACs separation columns and mMACS c-myc
isolation Kit (both from MiltenyiBiotec) and EZview RedAnti-HA affinity
gel (Sigma) were performed according to manufacturer’s instructions (see
Supplemental Experimental Procedures). Samples were analyzed by western
blotting.
Immunofluorescence
Subconfluent Vero E6 cells were used for immunofluorescence analysis (see
Supplemental Experimental Procedures). Pictures were taken using a Zeiss
200M fluorescent microscope. Images were analyzed by Axiovision Software
(Zeiss).
Reporter Gene Assay
293T cells were transfected with the following plasmids: pHHO1-ARE-Luc or
pmNQO1-ARE-Luc, phCMV-Nrf2, pSPORT6-Keap1, pRL-TK, and phCMV-
MARV-VP24 using TurboFect reagent. Cells were harvested 24 hr posttrans-
fection for measurement of luciferase activities (Renilla and Firefly) by the
Dual-Glo-Luciferase kit (Promega) (see Supplemental Experimental Proce-
dures). Data were expressed as fold induction compared to negative control.
In Vivo Studies
Wild-type or Nrf2/ C57BL6 mice (n = 12 per group) were infected with
mouse-adapted Marburgvirus RAVN (ma-RAVV) variant RAVN at a dose of
1,000 pfu/animal. Animals were monitored daily for weight loss and appear-
ance of other symptoms (see Supplemental Experimental Procedures). The
Institutional Animal Care and Use Committee of the United States Army
Medical Research Institute of Infectious Diseases (USAMRIID) approved these
studies.1034 Cell Reports 6, 1026–1036, March 27, 2014 ª2014 The AuthorsSUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2014.02.027.
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